tbuckley/cabot-search huggingface dataset:
Bright spots physical activity investments that work: Youth-Physical Activity Towards Health (Y-PATH)
Authors: Sarahjane Belton, Wesley O’Brien, Jamie McGann, Johann Issartel
Journal: British Journal of Sports Medicine (2018)

### Programme card

#### Country/locality/coverage

#### Target population

#### What modes/types/domains of physical activity does the programme promote?

#### Which of the seven best investments does the programme address?

#### What sectors does it involve?

#### Estimated programme reach

#### What is special about this programme?

#### Key contact

#### Programme website

The problem of low levels of youth physical activity (PA) participation in Ireland and internationally is clear and irrefutable.1 2 The Youth-Physical Activity Towards Health (Y-PATH) programme commenced in 2010, with cross-sectional research exploring predisposing and reinforcing factors influencing low levels of Irish youth PA participation (including fundamental movement skill (FMS) proficiency, and attitudes, motivation and knowledge towards PA).3 In consultation with key stakeholders a targeted ‘whole-school’ intervention programme was developed on the …
Real-Time Patient–Provider Video Telemedicine Integrated with Clinical Care
Authors: Mary E Reed, Rahul Parikh, Jie Huang, Dustin W Ballard, Irwin Barr, Craig Wargon
Journal: New England Journal of Medicine (2018)

Video Telemedicine Integrated with Clinical Care An integrated delivery system introduced video-visit capability for all clinicians in 2014. More than 150,000 patients participated in video visits ...
Thyroid Nodule DNA Methylation Signatures: An Important Diagnostic Annotation
Authors: Elliot J. Mitmaker, Roger Tabah, Jacques How
Journal: Clinical Cancer Research (2018)

Molecular profiling in thyroid cancer has made significant progress in part due to advances in somatic mutation profiling. Yet, differentiating benign from malignant thyroid nodules remains elusive. A unique set of DNA methylation signatures has the potential of improving thyroid cancer molecular diagnostics based on the DNA methylome.See related article by Yim et al., p. 544.
Abstract P053: Glycated Hemoglobin in Relation to Incident Diabetes and Cardiovascular Disease in Non-diabetic Adults
Authors: Patricia A Metcalf, Cam Kyle, Tim Kenealy, Susan Wells, Rod T Jackson
Journal: Circulation (2016)

Introduction: We compared the utility of glycated hemoglobin (HbA1c) and oral glucose tolerance (oGTT) in non-diabetic patients for identifying incident diabetes, all-cause mortality, cardiovascular disease (CVD) mortality, all-CVD events, coronary heart disease (CHD) events, ischaemic stroke events and diabetes microvascular complications. Hypothesis: HbA1c will provide the similar information to an oGTT. Methods: Data from a New Zealand community setting were prospectively linked to hospitalization, mortality, pharmaceutical and laboratory test results data. After applying exclusion criteria (prior laboratory diagnosis or history of drug treatment for diabetes or hospitalisation for diabetes or CVD event), there were 31,148 adults who had an HbA1c and 2-hr 75g oGTT. HbA1c was measured by ion-exchange high-performance liquid chromatography, and glucose using a commercial enzymatic method. We compared glycaemic measures and outcomes using multivariable Cox proportional hazards regression. Results: The median follow-up time was 4 years (range 0 to 13). The mean age was 57.6 years and 53.0% were male. After adjusting for other glycaemic measures (fasting glucose, 2-hr glucose and/or HbA1c where relevant) in addition to age, sex and ethnicity, the hazard ratios for incident diabetes, and diabetes complications of retinopathy, nephropathy and neuropathy were highest for 2-hr postchallenge glucose levels, followed by HbA1c and lastly by fasting plasma glucose. However, all-cause mortality was significantly associated with HbA1c concentrations only. CHD events were most strongly associated with HbA1c, followed by 2-hr glucose and circulatory complications showed stronger associations with HbA1c. Conclusion: HbA1c showed stronger associations with adverse outcomes compared to fasting glucose and provides a convenient alternative to an oGTT.
KEYNOTE-151: A phase Ib study of second-line pembrolizumab (Pembro) for Chinese patients (pts) with advanced or metastatic melanoma
Authors: L. Si, X. Zhang, Y. Shu, H. Pan, D. Wu, J. Liu, F. Lou, X. Wang, X. Wen, Y. Gu, L. Zhu, S. Lan, X. Cai, Y. Zhou, J. Ge, J. Li, H. Wu, J. Guo
Journal: Annals of Oncology (2018)
Cellulose based polymers in development of amorphous solid dispersions
Authors: Rahul B Chavan, Sneha Rathi, Vaskuri G S Sainaga Jyothi, Nalini R Shastri
Journal: Asian Journal of Pharmaceutical Sciences (2018)

Cellulose derivatives have gained immense popularity as stabilizers for amorphous solid dispersion owing to their diverse physicochemical properties. More than 20 amorphous solid dispersion-based products that have been approved for marketing consist of cellulose derivatives as stabilizers, thus highlighting their importance in generation of amorphous solid dispersions. These polymers offer numerous advantages like drug solubilization, crystallization inhibition and improvement in release patterns of drugs. Exploring their potential and exploiting their chemistry and pH responsive behaviour have led to the synthesis of new derivatives that has broadened the scope of the use of cellulose derivatives in amorphous formulation development. The present review aims to provide an overview of different mechanisms by which these cellulose derivatives inhibit the crystallization of drugs in the solid state and from supersaturated solution. A summary of different categories of cellulose derivatives along with the newly explored polymers has been provided. A special segment on strengths, weaknesses, opportunities, and threats (SWOT) analysis and critical quality attributes (CQAs) which affect the performance of the cellulose based amorphous solid dispersion will aid the researchers in identifying the major challenges in the development of cellulose based solid dispersion and serve as a guide for further formulation development.
The Lineage-Defining Transcription Factors SOX2 and NKX2-1 Determine Lung Cancer Cell Fate and Shape the Tumor Immune Microenvironment
Authors: Gurkan Mollaoglu, Alex Jones, Sarah J. Wait, Anandaroop Mukhopadhyay, Sangmin Jeong, Rahul Arya, Soledad A. Camolotto, Timothy L. Mosbruger, Chris J. Stubben, Christopher J. Conley, Arjun Bhutkar, Jeffery M. Vahrenkamp, Kristofer C. Berrett, Melissa H. Cessna, Thomas E. Lane, Benjamin L. Witt, Mohamed E. Salama, Jason Gertz, Kevin B. Jones, Eric L. Snyder, Trudy G. Oliver
Journal: Immunity (2018)
Immunotherapy in elderly patients (≥ 75 yrs) with advanced non-small cell lung cancer (NSCLC): A multicenter Italian experience
Authors: A. Luciani, L. Toschi, S. Fava, D. Cortinovis, V. Filipazzi, A. Tuzi, A. Marra, S. Rossi, A. Rossi, M. Blasi, M. Violati, L. Sala, F. Agustoni, P. Bidoli, S. Zonato, D. Ferrari
Journal: Annals of Oncology (2018)
Bone Regeneration: Embryonic‐Like Mineralized Extracellular Matrix/Stem Cell Microspheroids as a Bone Graft Substitute (Adv. Healthcare Mater. 19/2018)
Authors: Cuicui Fu, Dan Luo, Min Yu, Nan Jiang, Dawei Liu, Danqing He, Yu Fu, Ting Zhang, Yiqiang Qiao, Yanheng Zhou, Yan Liu
Journal: Advanced Healthcare Materials (2018)

In article 1800705, Yanheng Zhou, Yan Liu, and co-workers, fabricate embryonic-like mineralized extracellular matrix/stem cell microspheroids (MECS), which provide a physiological microenvironment conducive to intracellular communication and osteogenesis, leading to excellent bone regeneration outcomes. This study demonstrates the feasibility of MECS transplantation as a promising scaffold-free strategy for cell-based bone regenerative therapy in tissue engineering.
Demographic and Treatment Variables Influencing Outcome for Localized Paratesticular Rhabdomyosarcoma: Results From a Pooled Analysis of North American and European Cooperative Groups
Authors: David O. Walterhouse, Donald A. Barkauskas, David Hall, Andrea Ferrari, Gian Luca De Salvo, Ewa Koscielniak, Michael C.G. Stevens, Hélène Martelli, Guido Seitz, David A. Rodeberg, Margarett Shnorhavorian, Roshni Dasgupta, John C. Breneman, James R. Anderson, Christophe Bergeron, Gianni Bisogno, William H. Meyer, Douglas S. Hawkins, Veronique Minard-Colin
Journal: Journal of Clinical Oncology (2018)

Treatment recommendations for localized paratesticular rhabdomyosarcoma (PT RMS) differ in North America and Europe. We conducted a pooled analysis to identify demographic features and treatment choices that affect outcome.
Outbreak of multidrug-resistant tuberculosis in South Africa undetected by WHO-endorsed commercial tests: an observational study
Authors: Ndivhuho A Makhado, Edith Matabane, Mauro Faccin, Claire Pinçon, Agathe Jouet, Fairouz Boutachkourt, Léonie Goeminne, Cyril Gaudin, Gugu Maphalala, Patrick Beckert, Stefan Niemann, Jean-Charles Delvenne, Michel Delmée, Lufuno Razwiedani, Maphoshane Nchabeleng, Philip Supply, Bouke C de Jong, Emmanuel André
Journal: The Lancet Infectious Diseases (2018)
Abstract 19587: Timing of Advanced Airway Placement After Out-of-Hospital Cardiac Arrest: Earlier is Better
Authors: Justin L Benoit, Jason T McMullan, Henry E Wang, Changchun Xie, Kimberly W Hart, Christopher J Lindsell
Journal: Circulation (2017)

Introduction: Placement of an advanced airway (e.g. endotracheal tube, supraglottic airway) by Emergency Medical Services (EMS) for patients with out-of-hospital cardiac arrest (OHCA) is controvers...
Thyroid hormones and lung cancer: Primary hypothyroidism is prognostically significant for survival in lung cancer
Authors: Aleck Hercbergs, James Mason, Chandana Reddy, Paul Elson
Journal: Cancer Research (2004)

4440  Anecdotal reports and recent data suggest that decreased thyroid function may be associated with improved outcomes in lung and other solid tumors.Recently in a large population based study of patients treated for hyperthyroidism by radio-iodine ablation of the thyroid, long term follow up showed a signicantly lower prevalence and risk of dying from lung cancer .L-thyroxine [T4] which is commonly supplemented in hypothyroidism may,however, not correct intracellular hypothyroidism in tissues such as lung or restore blood IGF-1 to euthyroid levels . There is evidence too that tri-iodothyronine [T3] is a significant tumor mitogen, upregulates cyclin D1, E and modulates the IGF-1 and EGF-R growth factor systems. This multicenter study was aimed at determining the prognostic value of primary hypothyroidism on survival in lung cancer. METHODS: A hospital-based retrospective case-control study was conducted on 1979 patients with AJCC stages 1- 4 non -small cell and small cell lung cancer treated between January 1996 and July 2002. Patients with a clinical diagnosis of hypothyroidism based on documentation of thyroid hormone supplementation were individually matched to controls based on cancer histology, stage of disease, age, race, and gender. Kaplan-Meier survival curves were generated for each group. Age of cancer diagnosis for the 85 hypothyroid patients and the 1372 euthyroid patients before matching was compared. RESULTS: Overall, 85 hypothyroid cases[4.2%] and 85 matched controls were identified of which 70 were non-small cell and 15 small cell types The female: male ratio was 3.35:1. Primary tumor stage was Stage 1 :- 19 patients, Stage 2 :- 19 patients, Stage 3 :- 86 patients, and Stage 4 :- 46 patients.For AJCC stages 1-4 median survival [M.S.] was 14.5 months in the hypothyroid group and 11.1 months in the euthyroid group( p = .014) . For stage 4, M.S. was 11 vs.5 months(p= .0018). . Median age at diagnosis was 73 for hypothyroid vs. 64 years for euthyroid patients (p = .0006). CONCLUSION:This retrospective case control study suggests that primary hypothyroidism is prognostically significant and associated with a more indolent course in lung cancer.
Bone marrow transplantation generates T cell–dependent control of myeloma in mice
Authors: Slavica Vuckovic, Simone A. Minnie, David Smith, Kate H. Gartlan, Thomas S. Watkins, Kate A. Markey, Pamela Mukhopadhyay, Camille Guillerey, Rachel D. Kuns, Kelly R. Locke, Antonia L. Pritchard, Peter A. Johansson, Antiopi Varelias, Ping Zhang, Nicholas D. Huntington, Nicola Waddell, Marta Chesi, John J. Miles, Mark J. Smyth, Geoffrey R. Hill
Journal: Journal of Clinical Investigation (2018)

Transplantation with autologous hematopoietic progenitors remains an important consolidation treatment for patients with multiple myeloma (MM) and is thought to prolong the disease plateau phase by providing intensive cytoreduction. However, transplantation induces inflammation in the context of profound lymphodepletion that may cause hitherto unexpected immunological effects. We developed preclinical models of bone marrow transplantation (BMT) for MM using Vk*MYC myeloma-bearing recipient mice and donor mice that were myeloma naive or myeloma experienced to simulate autologous transplantation. Surprisingly, we demonstrated broad induction of T cell-dependent myeloma control, most efficiently from memory T cells within myeloma-experienced grafts, but also through priming of naive T cells after BMT. CD8+ T cells from mice with controlled myeloma had a distinct T cell receptor (TCR) repertoire and higher clonotype overlap relative to myeloma-free BMT recipients. Furthermore, T cell-dependent myeloma control could be adoptively transferred to secondary recipients and was myeloma cell clone specific. Interestingly, donor-derived IL-17A acted directly on myeloma cells expressing the IL-17 receptor to induce a transcriptional landscape that promoted tumor growth and immune escape. Conversely, donor IFN-γ secretion and signaling were critical to protective immunity and were profoundly augmented by CD137 agonists. These data provide new insights into the mechanisms of action of transplantation in myeloma and provide rational approaches to improving clinical outcomes.
Reply to Rajchgot <i>et al.</i>: Combination Nintedanib and Pirfenidone for Treatment of Idiopathic Pulmonary Fibrosis
Authors: Carlo Vancheri, Michael Kreuter, Luca Richeldi, Manuel Quaresma, Susanne Stowasser, Wim A. Wuyts
Journal: American Journal of Respiratory and Critical Care Medicine (2018)
Profound Perturbation of the Metabolome in Obesity Is Associated with Health Risk
Authors: Elizabeth T. Cirulli, Lining Guo, Christine Leon Swisher, Naisha Shah, Lei Huang, Lori A. Napier, Ewen F. Kirkness, Tim D. Spector, C. Thomas Caskey, Bernard Thorens, J. Craig Venter, Amalio Telenti
Journal: Cell Metabolism (2018)

Obesity is a heterogeneous phenotype that is crudely measured by body mass index (BMI). There is a need for a more precise yet portable method of phenotyping and categorizing risk in large numbers of people with obesity to advance clinical care and drug development. Here, we used non-targeted metabolomics and whole-genome sequencing to identify metabolic and genetic signatures of obesity. We find that obesity results in profound perturbation of the metabolome; nearly a third of the assayed metabolites associated with changes in BMI. A metabolome signature identifies the healthy obese and lean individuals with abnormal metabolomes—these groups differ in health outcomes and underlying genetic risk. Specifically, an abnormal metabolome associated with a 2- to 5-fold increase in cardiovascular events when comparing individuals who were matched for BMI but had opposing metabolome signatures. Because metabolome profiling identifies clinically meaningful heterogeneity in obesity, this approach could help select patients for clinical trials.
Phase II multicenter, single arm, open label study of nivolumab in combination with ipilimumab in untreated patients with metastatic uveal melanoma (GEM1402.NCT02626962)
Authors: J.M. Piulats Rodriguez, L. De La Cruz Merino, E. Espinosa, L. Alonso Carrión, S. Martin Algarra, R. López-Castro, M.T. Curiel García, D. Rodriguez Abreu, A.J. Rullan Iriarte, A. Berrocal Jaime
Journal: Annals of Oncology (2018)
Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy
Authors: Mizuki Nishibatake Kinoshita, Tatsuya Minami, Ryosuke Tateishi, Taijiro Wake, Ryo Nakagomi, Naoto Fujiwara, Masaya Sato, Koji Uchino, Kenichiro Enooku, Hayato Nakagawa, Yoshinari Asaoka, Shuichiro Shiina, Kazuhiko Koike
Journal: Journal of Hepatology (2018)
GW29-e1896 Contrast-Enhanced Ultrasonography in the detection for central venous obstruction after catheterization for the treatment of subclavian vein stenosis in hemodialysis patient: a case report and review of literatures
Authors: Yanling Zheng, Meiqing Cheng, Wenjuan Tong, Zuanan Chen, Shaohong Wu
Journal: Journal of the American College of Cardiology (2018)
Global warming: experts demand urgent action to prevent public health crisis
Authors: Vijay Shankar Balakrishnan
Journal: BMJ (2018)

Inaction on global warming will pose grave public health problems, climate experts have warned.

A report by the UN’s Intergovernmental Panel on Climate Change1 said that reducing the rise in the global temperature by just half a degree would help prevent major public health problems such as deadly heatwaves, the spread of disease, and poverty.

The review was commissioned by policy makers to report on the potential impact of keeping global warming to a maximum of 1.5°C above pre-industrial levels. This is 0.5°C lower …
First Look at Control-IQ: A New-Generation Automated Insulin Delivery System
Authors: Sue Brown, Dan Raghinaru, Emma Emory, Boris Kovatchev
Journal: Diabetes Care (2018)

To pilot test a new closed-loop control technology to validate it for a further large clinical trial.The t:slim X2 insulin pump with Control-IQ Technology (Tandem Diabetes Care) includes a Dexcom G6 sensor and a closed-loop algorithm implemented in the pump that 1) automates insulin correction boluses, 2) has a dedicated hypoglycemia safety system, and 3) gradually intensifies control overnight, aiming for blood glucose levels of approximately 100-120 mg/dL every morning.Five patients with type 1 diabetes (mean age 52.8 years, 2/3 male/female, mean A1C 6.5%) used Control-IQ in an outpatient setting (hotel) for approximately 37 h. During the closed loop, mean glucose was 129 mg/dL (135/121 mg/dL during the day/night), time within target range 70-180 mg/dL was 87% (82%/94% during the day/night), and time <60 mg/dL was 1.1% (2.0%/0.0% during the day/night).Following this pilot trial, Control-IQ was deployed in several studies, including the large-scale National Institutes of Health International Diabetes Closed-Loop (iDCL) Trial.
Abstract 15864: Patients With Acute Coronary Syndromes and Heart Failure Admitted to Critical Care Units in Teaching Hospitals Have Lower Observed In-hospital Mortality and 30-day Readmission Rates
Authors: Sanam Verma, Padma Kaul, Meng Lin, Justin A Ezekowitz, David Zygun, Finlay McAlister, Sean van Diepen
Journal: Circulation (2016)

Background: Acute coronary syndromes (ACS) and heart failure (HF) are leading diagnoses in patients admitted to coronary care units (CCU). However, it is unknown if the hospital type, including siz...
Abstract 15380: A Randomized Double Blind Placebo Controlled Trial of Metoprolol and Aspirin in Early Bereavement
Authors: Geoffrey Tofler, Monica Spinaze, Jill Dent, Marie-Christine Morel-Kopp, Roger Bartrop, Christopher Ward, Sharon McKinley, Anastasia Mihailidou, Jennifer Havyatt, Victoria Whitfield, Judith Fethney, Holly Prigerson, Thomas Buckley
Journal: Circulation (2016)

Introduction: Bereavement has been associated with an increased risk of cardiovascular disease (CVD), with a fourfold higher rate of non-fatal myocardial infarction in the first month. However, no ...
Isoform-specific AKT inhibition differentially affects cell functions in pancreatic adenocarcinoma
Authors: H. Arasanz, M. Gato-Cañas, M. Zuazo, M. Ibáñez-Vea, G. Fernández-Hinojal, J. Fernandez-Irigoyen, E. Santamaria, G. Kochan, R. Vera, D. Escors
Journal: Annals of Oncology (2018)
Polyreactive IgM initiates complement activation by PF4/heparin complexes through the classical pathway
Authors: Sanjay Khandelwal, Joann Ravi, Lubica Rauova, Alexandra Johnson, Grace M. Lee, Jennifer B. Gilner, Sreenivasulu Gunti, Abner L. Notkins, Maragatha Kuchibhatla, Michael Frank, Mortimer Poncz, Douglas B. Cines, Gowthami M. Arepally
Journal: Blood (2018)
GW29-e0785 Statin in combination with β-blocker therapy reduces the risk of major adverse cardiovascular events in patients with acute coronary syndrome
Authors: Ling Zhu, Yin Liu, Zhongwei Liu, Fuqiang Liu, Shuo Pan, Na Zhao, Yong Zhang, Xin Jiang, Gongchang Guan, Junkui Wang
Journal: Journal of the American College of Cardiology (2018)
GW29-e0145 Interleukin-10 -1087A/G promoter gene polymorphism is associated with coronary heart disease risk in a Chinese Han population
Authors: HaiFeng Zhang, YangXin Chen, YongQing Lin, ShaoHua Wang, ShuangLun Xie, ChengZhang Xu, JingFeng Wang
Journal: Journal of the American College of Cardiology (2018)
Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Authors: A. Madi, D. Fisher, T.S. Maughan, J.P. Colley, A.M. Meade, J. Maynard, V. Humphreys, H. Wasan, R.A. Adams, S. Idziaszczyk, R. Harris, R.S. Kaplan, J.P. Cheadle
Journal: Annals of Oncology (2018)
P3.17-12 Phase II Trial of Atezolizumab Before and After Chemoradiation for Unresectable Stage III NSCLC (AFT-16): Trial in Progress
Authors: H. Ross, D. Kozono, J. Urbanic, T. Williams, C. Dufrane, I. Bara, M. Gandhi, K. Schulze, J.M. Brockman, X. Wang, E. Vokes, T. Stinchcombe
Journal: Journal of Thoracic Oncology (2018)
Evaluation of a possible link between immunotherapy (IO) and acute vascular events
Authors: J. Bar, K. Shulman, T. Kuznetsov, G. Markel, S. Daher, R. Berger, T. Golan, D. Urban, T. Sela, E. Shacham Shmueli, R. Klempfner, A. Talianski, A. Onn, E. Dudnik
Journal: Annals of Oncology (2018)